What is Zacks Research’s Forecast for TSE:BHC Q2 Earnings?

Bausch Health Companies Inc. (TSE:BHC) – Zacks Research upped their Q2 2026 earnings estimates for Bausch Health Companies in a research report issued to clients and investors on Wednesday, March 11th. Zacks Research analyst Team now expects that the company will post earnings of $1.28 per share for the quarter, up from their prior estimate of $1.27. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2027 earnings at $1.52 EPS and FY2028 earnings at $4.56 EPS.

BHC has been the topic of several other reports. Raymond James Financial raised Bausch Health Companies to a “hold” rating in a report on Monday, December 15th. Barclays raised Bausch Health Companies to a “hold” rating in a research note on Monday, December 8th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Bausch Health Companies Price Performance

Shares of TSE BHC opened at C$6.89 on Friday. The business has a fifty day moving average price of C$8.56 and a two-hundred day moving average price of C$9.07. The stock has a market capitalization of C$2.55 billion, a PE ratio of 16.40, a P/E/G ratio of 0.21 and a beta of 0.60. The company has a debt-to-equity ratio of -3,835.02, a current ratio of 1.47 and a quick ratio of 0.58. Bausch Health Companies has a fifty-two week low of C$5.91 and a fifty-two week high of C$11.97.

Bausch Health Companies (TSE:BHC) last issued its quarterly earnings results on Wednesday, February 18th. The company reported C($0.41) earnings per share (EPS) for the quarter. Bausch Health Companies had a negative return on equity of 20.27% and a net margin of 1.82%.The company had revenue of C$6.62 billion for the quarter.

Key Bausch Health Companies News

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Zacks raised near‑term quarter estimates: Q3 2027 EPS was lifted from $1.42 to $1.52 and Q2 2026 EPS was nudged from $1.27 to $1.28 — modest upside to near‑term growth expectations. Article Title
• Positive Sentiment: Zacks also bumped a few other quarterly forecasts: Q1 2027 (1.09 → 1.11) and Q4 2026 (1.46 → 1.49), which could support upcoming quarterly results if sales/margins follow. Article Title
• Neutral Sentiment: Zacks published a FY2028 EPS outlook of $4.56 and reiterates a consensus/current full‑year estimate near $5.55 — these longer‑range figures provide context but are farther from near‑term market reaction. Article Title
• Negative Sentiment: Several notable downward revisions: Q4 2027 cut substantially (from $1.47 to $1.32) and Q2 2027 cut (1.32 → 1.20) — these reductions suggest Zacks expects slower growth or margin pressure later in FY2027. Article Title
• Negative Sentiment: Zacks trimmed multiple other forecasts including Q3 2026 (1.50 → 1.44), Q1 2026 (1.13 → 1.10), FY2026 (5.37 → 5.32) and FY2027 (5.30 → 5.15), signaling lower expected earnings vs prior estimates and applying downward pressure to valuation. Article Title

Bausch Health Companies Company Profile

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.